Navigation Links
Miltenyi Biotec Announces Release of Viscover(TM) Preclinical Contrast Agents for in vivo Small Animal Imaging

BERLIN and BERGISCH GLADBACH, Germany, June 16, 2010 /PRNewswire/ -- Miltenyi Biotec today announces the worldwide release of the Viscover(TM) product line, offering researchers an unrivaled range of preclinical contrast agents for small animal in vivo imaging.

Viscover marks the result of a fruitful collaboration between Miltenyi Biotec GmbH and nanoPET Pharma GmbH. Within this strategic alliance, Miltenyi Biotec is responsible for the distribution of Viscover products developed and manufactured by nanoPET Pharma. The current Viscover portfolio comprises twenty-one contrast agents for the preclinical imaging modalities MRI, CT, Optical Imaging, Ultrasound and SPECT/PET, and this number is set to increase soon.

"This partnership offers researchers a unique and powerful portfolio of small animal in vivo imaging agents," explains Stefan Miltenyi, CEO of Miltenyi Biotec. "Both nanoPET Pharma and Miltenyi Biotec are committed to serving the biomedical research community with innovative high-quality imaging products throughout the world."

Commenting on the collaboration, Andreas Briel, CEO of nanoPET Pharma GmbH, said: "This landmark partnership brings together Miltenyi Biotec's excellence in worldwide customer support with nanoPET's exclusive range of contrast agents. Our scientists have years of experience in biomedical imaging, gained through strong affiliations with commercial and academic bodies."

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. With approx. 1100 employees in 18 countries, Miltenyi Biotec develops, manufactures, and commercializes innovations for both research and clinical applications. The portfolio provides integrated solutions for all areas covering sample preparation, cell separation, cell culture, flow cytometry, and molecular analysis.

Visit to learn more.

About nanoPET Pharma

Based in Berlin, nanoPET Pharma GmbH discovers and develops innovative pharmaceutical contrast agents for use with the complete range of preclinical imaging modalities. The comprehensive Viscover portfolio currently provides contrast agents for the MRI, CT, Ultrasound, Optical Imaging, SPECT and PET modalities.

    Visit to discover more.


    Miltenyi Biotec
    Prof. Dr. Uwe Heinlein, Corporate Communications,
    Miltenyi Biotec GmbH, +49-2204-8306-6590,

    nanoPET Pharma
    Carolin Schlueter, Corporate Communications,
    nanoPET Pharma GmbH, +49-30-890-49-740,

SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
2. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
5. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
6. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
7. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
8. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
9. Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
Post Your Comments:
(Date:11/30/2015)... PUNE, India , November 30, ... --> --> ... deal trends for 2010 - 2015 ... activity for a range of deal ... (M&A) and strategic alliances. ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
Breaking Medicine Technology:
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... to a new study by UPMC and KingMed Diagnostics ... over three years found that consultation with UPMC pathologists resulted in significantly altered ...
(Date:11/30/2015)... ... , ... Two years ago, Debbie Gregory, the CEO of, found herself ... Meditation (TM). After encouraging a number of veterans to go through the program, ... the talk. , TM is becoming one of the best alternative treatments for Post-Traumatic ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag ... exclusive channel partner for the Nutraceutical Specialties products into oral solid dosage in ... immediately. , “We are pleased to announce our expanded distribution agreement with ...
(Date:11/30/2015)... ... ... While powdered supplements and drinks can reduce food preparation time, locating the ... has found an easy to keep track of the scoop. , He developed a ... a canister or other container handy and readily accessible. As such, it prevents the ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy Mitchell ... top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the Window ... treatment of glaucoma and cataracts, and how a visit with his grandmother to her ...
Breaking Medicine News(10 mins):